Edition:
India

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
15 Dec 2017
Change (% chg)

$-0.02 (-1.16%)
Prev Close
$1.73
Open
$1.73
Day's High
$1.74
Day's Low
$1.70
Volume
30,334
Avg. Vol
88,458
52-wk High
$10.90
52-wk Low
$1.53

Latest Key Developments (Source: Significant Developments)

Cyclacel Pharmaceuticals Q3 loss per share $0.91 including items
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Cyclacel Pharmaceuticals Inc ::Cyclacel Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.91 including items.  Full Article

Tang Capital Partners Lp says 9.6 pct stake in Cyclacel Pharmaceuticals
Saturday, 20 Aug 2016 

Tang Capital Partners Lp:Tang Capital Partners Lp reports 9.6 pct passive stake in Cyclacel Pharmaceuticals Inc as of Aug 12 - SEC Filing.  Full Article

Cyclacel Pharma Q2 shr loss $1.01
Thursday, 11 Aug 2016 

Cyclacel Pharmaceuticals Inc : Cyclacel pharmaceuticals reports 2nd quarter 2016 financial results . Cyclacel pharmaceuticals q2 shr loss $1.01 . Cyclacel pharmaceuticals q2 revenue $200,000 vs $300,000 .Cyclacel says estimates that it has capital resources to reach beyond final analysis of seamless and continue existing programs through q1 of 2018.  Full Article

Cyclacel Pharmaceuticals may issue, sell shares having aggregate offering price of up to $4 mln through FBR
Friday, 24 Jun 2016 

Cyclacel Pharmaceuticals Inc :Sales agreement with FBR Capital Markets & Co; may issue, sell shares having aggregate offering price of up to $4 million through FBR.  Full Article

Cyclacel Pharmaceuticals files for mixed shelf of up to $100 mln - SEC filing
Saturday, 11 Jun 2016 

Cyclacel Pharmaceuticals Inc : Files for mixed shelf of up to $100 million - sec filing Source: (http://1.usa.gov/1WIQTTw ) Further company coverage: [CYCC.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Cyclacel Pharmaceuticals reports Q1 loss per share $0.09
Thursday, 12 May 2016 

Cyclacel Pharmaceuticals Inc : Cyclacel Pharmaceuticals Inc says estimates that it has capital resources to reach beyond final analysis of seamless and continue existing programs through end of 2017 . Cyclacel Pharmaceuticals reports first quarter 2016 financial results . Q1 loss per share $0.09 .Q1 revenue $100,000 versus $500,000.  Full Article